I
18.37
-0.42 (-2.24%)
| Previous Close | 18.79 |
| Open | 18.82 |
| Volume | 833,159 |
| Avg. Volume (3M) | 1,458,008 |
| Market Cap | 3,120,346,624 |
| Price / Book | 6.86 |
| 52 Weeks Range | |
| Earnings Date | 30 May 2025 - 6 Jun 2025 |
| Diluted EPS (TTM) | -2.62 |
| Total Debt/Equity (MRQ) | 0.01% |
| Current Ratio (MRQ) | 6.04 |
| Operating Cash Flow (TTM) | -324.94 M |
| Levered Free Cash Flow (TTM) | -187.67 M |
| Return on Assets (TTM) | -44.73% |
| Return on Equity (TTM) | -74.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Immunovant, Inc. | Bearish | Bearish |
AIStockmoo Score
0.4
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -4.0 |
| Average | 0.38 |
|
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 58.59% |
| % Held by Institutions | 49.64% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Deep Track Capital, Lp | 31 Dec 2024 | 6,000,000 |
| T. Rowe Price Investment Management, Inc. | 31 Dec 2024 | 5,117,234 |
| Alpine Global Management, Llc | 31 Dec 2024 | 2,158,904 |
| Perceptive Advisors Llc | 31 Dec 2024 | 2,139,199 |
| Baker Bros. Advisors Lp | 31 Dec 2024 | 1,707,881 |
| Viking Global Investors Lp | 31 Dec 2024 | 1,407,290 |
| Pictet Asset Management Holding Sa | 31 Mar 2025 | 1,188,578 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 51.00 (HC Wainwright & Co., 177.63%) | Buy |
| Median | 38.50 (109.58%) | |
| Low | 17.00 (UBS, -7.46%) | Hold |
| Average | 36.25 (97.33%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 18.09 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 22 Apr 2025 | 17.00 (-7.46%) | Hold | 14.25 |
| B of A Securities | 20 Mar 2025 | 33.00 (79.64%) | Buy | 19.69 |
| HC Wainwright & Co. | 19 Mar 2025 | 51.00 (177.63%) | Buy | 18.88 |
| 10 Feb 2025 | 51.00 (177.63%) | Buy | 19.52 | |
| Guggenheim | 10 Feb 2025 | 44.00 (139.52%) | Buy | 19.52 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |